Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by Maxim Group in a research report issued to clients and investors on Friday, March 29th, AnalystRatings.com reports. They presently have a $84.00 target price on the biopharmaceutical company’s stock. Maxim Group’s target price points to a potential upside of 33.44% from the stock’s previous close.
The analysts wrote, “Gilead and Galapagos NV (GLPG – NR) reported positive data from two P3 studies of JAK1 inhibitor filgotinib in treating rheumatoid arthritis (RA); FINCH-1 and FINCH-3. Recall the FINCH-2 trial read-out in 3Q18. All three trials met their primary endpoints as well as multiple secondary endpoints.””
GILD has been the subject of several other research reports. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Mizuho reiterated a “buy” rating and issued a $88.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 26th. Citigroup reiterated a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 5th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $82.12.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.78 EPS. As a group, analysts expect that Gilead Sciences will post 6.23 EPS for the current fiscal year.
In other news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $67.23, for a total value of $181,521.00. Following the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,869,758.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares in the company, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. Insiders have sold 42,102 shares of company stock valued at $2,787,375 over the last ninety days. Insiders own 0.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in Gilead Sciences in the fourth quarter worth approximately $27,000. Capital Financial Planning LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $27,000. Advisors Preferred LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $31,000. Legacy Financial Advisors Inc. grew its holdings in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 383 shares during the last quarter. Finally, Claybrook Capital LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $32,000. Institutional investors own 80.20% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.